Please provide your email address to receive an email when new articles are posted on . Data published in July in JAMA Ophthalmology showed that 0.01% atropine drops safely curbed myopia progression ...

Childhood myopia progression could be treated with low-dose atropine due to the safety and efficacy displayed in this study. The global prevalence of myopia was estimated to be 30% to 34% in 2020 and ...

A Prescription Drug User Fee Act target date of October 23, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Please provide your email address to receive an email when new articles are posted on . Vyluma Inc. has announced that the FDA will review its new drug application for NVK002, a preservative-free, low ...

Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, ...

Over 24 months, kids using the once-nightly drops and those using placebo saw mean changes in spherical equivalent refractive error (SER) of -0.82 D (95% CI -0.96 to ...

Share on Pinterest Experts say the incidence of nearsightedness in children is rising. Catherine Falls Commercial/Getty Images Experts say that developing nearsightedness as a child might be an ...

Children with myopia using 0.05% atropine eye drops had less myopia progression and/or less axial elongation compared with those using placebo or 0.01% atropine, though they had higher rates of ...

According to a secondary analysis of the 24- Month Myopia Outcome Study of Atropine in Children (MOSAIC) trial, 0.05% atropine eye drops were more effective in controlling myopia progression and axial ...

Credit: Getty Images. A PDUFA target date of January 31, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for NVK002 ...